top of page
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence
Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they...
MedMira
17. Apr.3 Min. Lesezeit
MedMira Announces Partnership with MediGroup Physician Services in the United States
Halifax, Nova Scotia, 27th of February, 2025  – MedMira Inc. (MedMira) (TSXV: MIR) announced today its partnership with MediGroup, a...
MedMira
27. Feb.3 Min. Lesezeit
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada.
Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement...
MedMira
25. Feb.3 Min. Lesezeit
MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications
MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications  Halifax,...
MedMira
21. Jan.5 Min. Lesezeit
Copy of MedMira receives Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for Point-of-Care use
Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from...
MedMira
14. Jan.3 Min. Lesezeit
Copy of MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia,  9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing...
MedMira
9. Jan.4 Min. Lesezeit
bottom of page